Related Experiment Video

Updated: Aug 16, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

[Vasoprotective effects of statins and angiotensin II blockers in atherothrombosis]

J Egido1, M Ruiz-Ortega, B Muñoz-García

  • 1Laboratorio de Patología Vascular y Nefrología Experimental, Fundación Jiménez Díaz, Universidad Autónoma de Madrid. jegido@fjd.es

Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia
|July 30, 2005
PubMed

Insights

Cardiovascular disease is a leading cause of death. Combining statins and angiotensin II blockers may improve outcomes for patients with atherothrombosis and hypertension.

Area of Science:

  • Cardiology and Pharmacology
  • Investigating cardiovascular disease pathogenesis and treatment strategies.

Background:

  • Cardiovascular disease, particularly atherothrombosis, represents a significant global mortality cause.
  • Current primary treatments include HMG-CoA reductase inhibitors (statins) for atherothrombosis and angiotensin II blockers for hypertension.

Purpose of the Study:

  • To explore the potential benefits of combining statins and angiotensin II blockers.
  • To evaluate the efficacy of concomitant therapy in managing cardiovascular and hypertensive diseases.

Main Methods:

  • Review of recent data and clinical findings on cardiovascular disease treatment.
  • Analysis of the pharmacological actions of statins and angiotensin II blockers.
  • Comparative assessment of monotherapy versus combination therapy.

Main Results:

  • Statins demonstrate efficacy in treating atherothrombotic cardiovascular disease.
  • Angiotensin II blockers are effective for hypertensive disease.
  • Emerging evidence suggests combined use of both drug classes may enhance therapeutic outcomes.

Conclusions:

  • Concomitant administration of statins and angiotensin II blockers shows promise for improved cardiovascular health.
  • This combination therapy warrants further investigation for managing complex cardiovascular conditions.

More Related Videos

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...